Heritage Pharma announces leadership changes

Heritage Pharmaceuticals Inc. announced Wednesday executive leadership changes at the East Brunswick-based pharmaceutical company.

William S. Marth has joined the company as CEO and president, North America and Europe, of the company’s parent, Heritage Pharma Holdings Inc. Marth has also been appointed as member of the company’s board of directors and member of the board of directors for two of its affiliates, Marcan Pharmaceuticals and Emcure Pharma UK Limited.

Prior to his appointment, Marth was CEO and president of AMRI. Before that, he was at Teva Pharmaceuticals, as CEO and president of Teva Americas.

Heritage also announced that John W. Denman has joined the company as president.

Denman joins Heritage from Renaissance SSA LLC, where he was CEO and president in charge of the sterile products division.  Previously, he was at Renaissance Pharma Inc., Teva Pharmaceuticals and Sandoz Inc.

“We are very pleased that Bill Marth and John Denman have decided to join our team.  Bill is a recognized leader in the pharmaceutical industry who possesses invaluable expertise in formulating and executing strategic initiatives that have transformed pharmaceutical businesses.  John is another great addition to the leadership team, having worked closely with Bill during his tenure with Teva,” said Marvin Samson, chairman of the Heritage board of directors.

“I am very pleased to accept the role of President and Chief Executive Officer, North America and Europe for the Company during this exciting time.  The Emcure family, Mr. Samson, and the entire Heritage team have built a very successful company and I look forward to continuing that tradition of success by executing on the current strategies, as well as identifying new opportunities to create additional value for Heritage,” Marth said.